MorphoSys AG (NASDAQ:MOR)
| 5.05 Delayed Data As of Jul 01 |  +0.22 / +4.55%Today’s Change | 4.35 Today|||52-Week Range 19.83 | -46.39% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $684.3M |
Company Description
MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Contact Information
MorphoSys AG Semmelweisstrasse 7 Planegg Bayern (bavaria) 82152 |
Employees
Shareholders
| Other institutional | 1.63% |
| Mutual fund holders | 0.47% |
| Individual stakeholders | -- |
Top Executives
| Jean-Paul Kress | CEO & Chairman-Management Board |
| Sung H. Lee | Chief Financial Officer |
| Malte Peters | Chief Research & Development Officer |
| Daniel Palmacci | Global Head-Technical Operations |
| Charlotte Lohmann | Senior Vice President & General Counsel |
